老年2型糖尿病患者启用恩格列净相关的医疗资源利用与费用
基于美国Medicare按服务付费的65岁及以上2型糖尿病患者,比较启用恩格列净与二肽基肽酶4抑制剂(DPP-4i)者的医疗资源利用与费用,经1:1倾向评分匹配得到23,335对。恩格列净组住院天数、住院次数、急诊就诊和门诊就诊次数均较低,总费用较低,但糖尿病药物费用较高。
要点
- 恩格列净组住院天数(RR 0.89)、住院次数(RR 0.86)、急诊就诊(RR 0.86)和门诊就诊(RR 0.96)均低于DPP-4i组。
- 恩格列净组总医疗费用较DPP-4i组低1,109美元/人年,但糖尿病药物费用高454美元/人年。
- 有心血管疾病史亚组总费用降低2,005美元/人年,无心血管疾病史亚组为296美元/人年且95%CI跨0。
核心结论
- 在老年2型糖尿病患者中,与DPP-4i相比,恩格列净与较低的住院天数、住院次数、急诊就诊和门诊就诊次数及较低医疗费用相关,在有心血管疾病史者中尤为明显。
研究设计与样本
- 美国Medicare按服务付费、年龄≥65岁的2型糖尿病患者,启用恩格列净或DPP-4i(2014年8月至2018年9月),经1:1倾向评分匹配调整143项基线协变量后分析。
- 共识别23,335对匹配对象,平均年龄72岁,51%有基线心血管疾病。
主要发现
- 恩格列净组对比DPP-4i组:住院天数RR 0.89(95%CI 0.82, 0.97),急诊就诊RR 0.86(0.82, 0.91),住院次数RR 0.86(0.79, 0.93),门诊就诊RR 0.96(0.95, 0.98)。
- 恩格列净组对比DPP-4i组:住院费用-713美元/人年(95%CI -847, -579),门诊费用-198美元/人年(-272, -124),总医疗费用-1,109美元/人年(-1,478, -739)。
- 恩格列净组糖尿病药物费用较DPP-4i组高454美元/人年(95%CI 284, 567)。
- 心血管疾病亚组总费用:恩格列净组对比DPP-4i组-2,005美元/人年(95%CI -2,451, -1,337);非心血管疾病亚组-296美元/人年(95%CI -740, 148)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We compared health care resource utilization (HCRU) and costs for inpatient and outpatient services and dispensed medications in older adults with type 2 diabetes initiating empagliflozin versus dipeptidyl peptidase 4 inhibitors (DPP-4is). RESEARCH DESIGN AND METHODS: The study population included U.S. Medicare fee-for-service beneficiaries with diabetes (age ≥65 years) initiating empagliflozin or DPP-4is (August 2014 to September 2018). We estimated rate ratios (RRs) for HCRU outcomes using zero-inflated negative binomial regression and per-member per-year (PMPY) cost differences using generalized linear model with gamma distributions, overall and stratified by baseline cardiovascular disease (CVD), after adjusting for 143 baseline covariates using 1:1 propensity score matching. RESULTS: We identified 23,335 matched pairs (mean age 72 years, 51% with baseline CVD). HCRU rates were lower in empagliflozin versus DPP-4i initiators (number of inpatient days, RR 0.89 [95% CI 0.82, 0.97]; number of emergency department [ED] visits, 0.86 [0.82, 0.91]; number of hospitalizations, 0.86 [0.79, 0.93]; number of office visits, 0.96 [0.95, 0.98]). Inpatient cost (-$713 PMPY [95% CI -847, -579), outpatient cost (-$198 PMPY [-272, -124]), and total cost of care (-$1,109 PMPY [-1,478, -739]) were lower for empagliflozin versus DPP-4is, although diabetes medication cost was higher in empagliflozin initiators ($454 PMPY [95% CI 284, 567]). In the CVD subgroup, total cost was lower for empagliflozin initiators (-$2,005 PMPY [-2,451, -1,337]), while the difference was attenuated in the non-CVD subgroup (-$296 PMPY [-740, 148]). CONCLUSIONS: Among older adults with diabetes, empagliflozin was associated with a lower number of inpatient days, hospitalizations, ED visits, and office visits and with lower costs of care compared with DPP-4is, especially in those with history of CVD.
引用
- Htoo PT, NajafZadeh M, Tesfaye H, et al. Health Care Utilization and Costs Associated With Empagliflozin in Older Adults With Type 2 Diabetes. Diabetes Care. 2024. PMID: 38917305. doi:10.2337/dc24-0270
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。